Related Experiment Video

Updated: Sep 19, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Future directions in plasminogen activator therapy

C Bode1, M S Runge, E Haber

  • 1Medical Clinic III (Cardiology), University of Heidelberg, Federal Republic of Germany.

Clinical Cardiology
|June 1, 1990
PubMed

Insights

Thrombotic disorders like heart attack and stroke are major health issues. New thrombolytic therapies aim to improve clot breakdown and reduce bleeding risks for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombotic disorders, including myocardial infarction and stroke, are primary causes of mortality and morbidity in industrialized countries.
  • Effective thrombolytic therapy is crucial for reducing infarct size, preserving cardiac function, and lowering mortality rates.
  • Current thrombolytic agents like streptokinase and urokinase can cause systemic breakdown of the hemostatic system, while more specific agents like tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) may still lead to bleeding complications at therapeutic doses.

Purpose of the Study:

  • To explore novel strategies for optimizing thrombolytic therapy by enhancing efficacy and minimizing bleeding risks.
  • To investigate advanced approaches such as synergistic combinations, modified activators, and targeted delivery systems for improved risk/benefit ratios.

Main Methods:

  • Review of existing thrombolytic agents and their limitations.
  • Exploration of emerging therapeutic strategies including synergistic combinations of plasminogen activators.
  • Discussion of engineered molecules such as mutants of t-PA and scu-PA, chimeric molecules, and antibody-targeted thrombolytic agents.

Main Results:

  • Synergistic combinations of plasminogen activators offer potential for improved efficacy.
  • Mutants and chimeric molecules of t-PA and scu-PA aim to enhance specificity and reduce bleeding.
  • Antibody-targeted thrombolytic agents present a promising approach for localized clot dissolution and modulation of clot components.

Conclusions:

  • Optimizing thrombolytic therapy requires innovative approaches to balance efficacy and safety.
  • Future directions involve developing targeted agents and synergistic combinations to improve treatment outcomes for thrombotic disorders.
  • Antibody-targeted strategies hold potential for precise delivery of fibrinolytic or antiplatelet functions to the clot site.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...